Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 425 GBX -0.35% Market Closed
Market Cap: 450.2m GBX
Have any thoughts about
Oxford BioMedica PLC?
Write Note

Oxford BioMedica PLC
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Oxford BioMedica PLC
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Oxford BioMedica PLC
LSE:OXB
Total Current Liabilities
ÂŁ59.1m
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
31%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Total Current Liabilities
$39.4m
CAGR 3-Years
66%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Total Current Liabilities
ÂŁ65.1m
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Total Current Liabilities
$56.4m
CAGR 3-Years
23%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Total Current Liabilities
ÂŁ139m
CAGR 3-Years
36%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Total Current Liabilities
ÂŁ150.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
7%
No Stocks Found

Oxford BioMedica PLC
Glance View

Market Cap
447.5m GBX
Industry
Biotechnology

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

OXB Intrinsic Value
365.05 GBX
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Oxford BioMedica PLC's Total Current Liabilities?
Total Current Liabilities
59.1m GBP

Based on the financial report for Jun 30, 2024, Oxford BioMedica PLC's Total Current Liabilities amounts to 59.1m GBP.

What is Oxford BioMedica PLC's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
31%

Over the last year, the Total Current Liabilities growth was 10%. The average annual Total Current Liabilities growth rates for Oxford BioMedica PLC have been 8% over the past three years , 12% over the past five years , and 31% over the past ten years .

Back to Top